Reasons for discontinuation of nevirapine-containing HAART: Results from an unselected population of a large clinical cohort

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 3, 2007, Pages 569-572

  Maggiolo, Franco ^a   Arici, Claudio ^a   Airoldi, Monica ^a   Ripamonti, Diego ^a   Quinzan, Giampaolo ^a   Gregis, Giampietro ^a   Ravasio, Veronica ^a   Bombana, Enrico ^a   Suter, Fredy ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Adverse events; Efficacy; NNRTIs; Non nucleoside reverse transcriptase inhibitors

Indexed keywords

ABACAVIR; DIDANOSINE; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC REACTION; AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL DECISION MAKING; CLINICAL TRIAL; COHORT ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEPATITIS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; KAPLAN MEIER METHOD; LIVER DYSFUNCTION; LIVER TOXICITY; LOGISTIC REGRESSION ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NEUROPATHY; OPEN STUDY; POPULATION RESEARCH; PREDICTION; RASH; RETROSPECTIVE STUDY; RISK ASSESSMENT; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SUPERINFECTION; VIRUS LOAD; DRUG ADMINISTRATION; STATISTICAL MODEL;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; NEVIRAPINE; RETROSPECTIVE STUDIES;

EID: 34248219982     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl534     Document Type: Article

References (10)

1. Montaner JS, Reiss P, Cooper D et al. A randomized, double blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-infected patients: The INCAS Trial. Italy, the Netherlands, Canada and Australia Study. JAMA 1998; 279: 930-7.
2. Negredo E, Cruz L, Paredes R et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis 2002; 34 504-10.
3. Idigbe EO, Adewole TA, Eisen G et al. Management of HIV-1 infection with a combination of nevirapine, stavudine and lamivudine: A preliminary report on the Nigerian antiretroviral program. J Acquir Immune Defic Syndr 2005; 40: 65-9.
4. Kumarasamy N, Vallabhaneni S, Cecelia AJ et al. Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India. J Acquir Immune Defic Syndr 2006; 41: 53-8.
5. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998; 47: 1-39.
6. Department of Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. 4 May 2006. www.hivatis.org (July 2006, date last accessed).
7. Ribeira E, Rodriguez-Pardo D, Rubio M et al. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients. Antivir Ther 2005; 10: 605-14.
8. van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs plus stavudine and lamivudine: A randomised open-label trial, the 2NN study. Lancet 2004; 363: 1253-63.
9. Sulkowski MS, Thomas DL, Mehta SH et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology 2002; 35: 182-9.
10. Stern JO, Robinson PA, Love J et al. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003; 34 Suppl 1: S21-33.